NZV930 / Coherus Oncology - LARVOL DELTA

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (Coherus Press Release) - "A Phase 2 study evaluating casdozokitug...in combination with toripalimab and bevacizumab in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma is expected to begin enrolling patients in Q4 2024...Research and development (R&D) expenses were $22.0 million and $23.3 million for the three months ended June 30, 2024 and 2023, respectively, and $50.4 million and $57.4 million for the six months ended June 30, 2024 and 2023, respectively....The decrease for the six-month period was partially offset by the net $6.8 million charge in the first quarter of 2024 associated with the full write-off of the outlicense intangible asset and associated release of the CVR liability related to NZV930, obtained in the Surface Oncology, Inc. acquisition."

Commercial • New P2 trial • Hepatocellular Cancer • Liver Cancer

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; Business reasons

Combination therapy • IO biomarker • Metastases • Trial termination • Oncology • Solid Tumor • PD-L1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=77 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=145 ➔ 77

Combination therapy • Enrollment change • Enrollment closed • IO biomarker • Metastases • Oncology • Solid Tumor • PD-L1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=145 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2025 ➔ Sep 2023 | Trial primary completion date: Feb 2025 ➔ Sep 2023

Combination therapy • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=145 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Feb 2025

Combination therapy • IO biomarker • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1

Novartis halts phase 1 cancer trial of CD73 antagonist over efficacy, but combo studies continue (FierceBiotech) - "Novartis has halted a phase 1 trial of its CD73 antagonist due to a low likelihood of efficacy, although the Big Pharma will continue to explore the therapy’s potential as part of a combo regimen. The trial of NZV930 was 'terminated early because data review showed low likelihood of efficacy in the patients recruited in that clinical setting,' a Novartis spokesperson confirmed to Fierce Biotech. The decision was not safety-related, they added."

Trial termination • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies (AACR 2022) - P1 | "NZV930 reduced adenosine levels in plasma and tumors. The RDE of NZV930 SA or in combination with spartalizumab and/or taminadenant is 600 mg Q2W with a step-up dosing regimen. NZV930 SA and its combinations exhibited a tolerable safety profile in multiple advanced solid tumors and showed good PK properties."

Clinical • Combination therapy • IO biomarker • P1 data • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • NT5E

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (clinicaltrials.gov) - P1 | N=127 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; After review of data which showed low likelihood of efficacy in these patients Novartis decided to terminate the trial early. Termination was not safety related

Combination therapy • Trial termination • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (clinicaltrials.gov) - P1 | N=127 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=344 ➔ 127 | Trial completion date: Mar 2023 ➔ Sep 2022 | Trial primary completion date: Mar 2023 ➔ Sep 2022

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (clinicaltrials.gov) - P1 | N=344 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: Sep 2022 ➔ Mar 2023

Combination therapy • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (clinicaltrials.gov) - P1; N=344; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Feb 2022 ➔ Apr 2023; Trial primary completion date: Jan 2022 ➔ Sep 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

"Is nzv930 the antibody formerly known as srf373?" (@WillPeterman3)

"Thanks Brad. I've added $SURF (NZV930 in solid tumors) and $TCON (TJ004309 in solid tumors) to Mara's CD73 list and published a spreadsheet at: https://t.co/TQp4PtIdUj" (@Mazeraski)

Oncology • Solid Tumor • CD73

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=145; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Oncology • Solid Tumor

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=145; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • Combination therapy • New P1 trial

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019 (GlobeNewswire, Surface Oncology, Inc.) - Presented preclinical data further supporting the anti-tumor mechanisms for SRF617 (targeting CD39; currently in IND-enabling studies) and NZV930 (targeting CD73; currently in phase 1) at the Brisbane Immunotherapy 2019 Conference in May. The ongoing phase 1b study of NZV930 (CD73), licensed to Novartis, is continuing to enroll and is evaluating combinations of NZV930 with PDR001 (anti PD-1), NIR178 (A2aR inhibitor), as well as a triplet combination of all three therapies. Submitted multiple abstracts for presentation at the Society for the Immunotherapy of Cancer (SITC) Conference discussing data from the SRF617, SRF388 and SRF231 programs. Continued preparation to file Investigational New Drug applications for both SRF617 and SRF388 in Q4 of 2019. These filings will be staggered, with the IND for SRF617 to be filed first.

Commercial • Preclinical • Regulatory • Tumor microenvironment

Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019 (GlobeNewswire, Surface Oncology, Inc.) - Pam’s presentation highlights additional validating data of the NZV930 program candidate, a highly potent enzymatic inhibitor of CD73, and its ability to block the production of extracellular adenosine in the TME,” said Vito Palombella, Ph.D., chief scientific officer of Surface. Also, by reducing adenosine, in a manner similar to NZV930, we see increased proliferation of tumor-targeting T cells.

Preclinical • Tumor microenvironment

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019 (GlobeNewswire, Surface Oncology, Inc.) - The Novartis-sponsored phase 1 trial of NZV930 (CD73) continues to progress, now enrolling patients in seven countries

Enrollment status • IO Biomarker • Tumor microenvironment

"Option declined: @Novartis turned down an option on SRF-388, @SurfaceOncology's monoclonal antibody targeting IL-27, but continues development of the CD73-targeting antibody SRF-373 (now NZV-930), now it phase I. One more option remains." (@BioWorld)